Combined remodeling control therapy and anti-remodeling therapy by implantable cardiac device

• US 7,805,193 B2
• Filed: 07/13/2007
• Issued: 09/28/2010
• Est. Priority Date: 05/20/2004
• Status: Expired due to Fees

• Current Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Original Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Inventors: Moffitt, Julia, Manicka, Yatheendhar D., KenKnight, Bruce H., Libbus, Imad
• Primary Examiner(s): Evanisko; George R
• Assistant Examiner(s): HAYES, ANDREW L
• Application Number:
  US11/777,394
• Publication Number:
  US 20080015648A1
• Time in Patent Office: 1,173 Days
• Field of Search: 607/9, 607/11, 607/17, 607/18, 607/19, 607/23, 607/24
• US Class Current: 607/11
• CPC Class Codes: A61N 1/36114 Cardiac control, e.g. by vagal stimulation stimulating the heart A61N1/362
• CPC Class Codes: A61N 1/362 Heart stimulators heart defibrillators A61N1/39
• CPC Class Codes: A61N 1/3627 for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy

Abstract

A method and device for delivering ventricular resynchronization pacing therapy in conjunction with electrical stimulation of nerves which alter the activity of the autonomic nervous system is disclosed. Such therapies may be delivered by an implantable device and are useful in preventing the deleterious ventricular remodeling which occurs as a result of a heart attack or heart failure. The device may perform an assessment of cardiac function in order to individually modulate the delivery of the two types of therapy.

Claims

1. An implantable device for delivering cardiac therapy to a patient, comprising:

one or more pulse generators for generating pacing pulses and neural stimulation pulses;

a parasympathetic stimulation channel for stimulating parasympathetic nerve activity by delivering neural stimulation pulses;

a sensor for measuring cardiac output;

a controller for controlling the delivery of pacing pulses to one or more ventricular sites during a cardiac cycle in accordance with a programmed pacing mode;

wherein the controller is programmed to deliver remodeling control therapy (RCT) by controllably delivering ventricular pacing in a manner which pre-excites a region of the ventricular myocardium so as to mechanically unload that region during systole;

wherein the controller is further programmed to deliver anti-remodeling therapy (ART) by controlling stimulation of parasympathetic nerve activity via the parasympathetic stimulation channel;

wherein the controller is programmed to perform an assessment of cardiac function and to modulate the delivery of RCT and ART in accordance with the assessment of cardiac function, wherein the assessment of cardiac function includes the measurement of cardiac output; and

,

wherein ART is modulated in response to the assessment of cardiac function by varying the amplitude of the neural stimulation pulses.

2. The device of claim 1 further comprising a neural inhibition channel for inhibiting sympathetic nerve activity and wherein the anti-remodeling therapy delivered by the controller further includes inhibition of sympathetic nerve activity.

3. The device of claim 1 wherein the parasympathetic stimulation channel includes a nerve cuff electrode adapted for disposition around a parasympathetic nerve.

4. The device of claim 1 wherein the parasympathetic stimulation channel includes an electrode adapted for intravascular disposition in order to transvascularly stimulate a parasympathetic nerve adjacent a blood vessel.

5. The device of claim 1 wherein the cardiac output sensor is a trans-thoracic impedance measuring circuit.

6. The device of claim 1 further comprising an arterial blood pressure sensor and wherein the cardiac function assessment further includes the measured blood pressure.

7. The device of claim 1 further comprising an exertion level sensor for measuring the patient'"'"'s exertion level, and wherein the cardiac function assessment further includes the measured exertion level.

8. The device of claim 1 further comprising a sensing channel for detecting cardiac activity;

circuitry for measuring heart rate variability based on the sensed cardiac activity and for assessing the patient'"'"'s autonomic balance based on the measured heart rate variability; and

wherein the cardiac function assessment further includes the assessment of the patient'"'"'s autonomic balance based upon heart rate variability.

9. The device of claim 1 wherein RCT is modulated in response to the assessment of cardiac function by varying the extent of pre-excitation provided to a ventricular pacing site.

10. The device of claim 1 wherein ART is further modulated in response to the assessment of cardiac function by varying the amplitude, frequency, or duty cycle of parasympathetic stimulation pulses.

11. The device of claim 1 wherein the controller is programmed to deliver RCT as biventricular pacing so as to pre-excite one of the ventricles relative to the other.

12. The device of claim 1 wherein the controller is programmed to deliver RCT as multi-site ventricular pacing where at least one of the ventricles is paced at a plurality of sites so as to pre-excite one or more of the sites relative to the other sites.

13. The device of claim 1 wherein the controller is programmed to deliver RCT as left ventricle-only pacing which pre-excites the left ventricle relative to the right ventricle during systole.

14. A method for operating a cardiac device to deliver cardiac therapy to a patient, comprising:

delivering remodeling control therapy (RCT) by controllably delivering ventricular pacing through one or more pacing channels in accordance with a programmed mode in a manner which pre-excites a region of the ventricular myocardium so as to mechanically unload that region during systole;

delivering anti-remodeling therapy (ART) by controlling stimulation of parasympathetic nerve activity via a parasympathetic stimulation channel;

measuring cardiac output; and

,

performing an assessment of cardiac function and modulating the delivery RCT and ART in accordance with the assessment of cardiac function, wherein the assessment of cardiac function includes the measured cardiac output and wherein ART is modulated by varying an amplitude of the parasympathetic nerve stimulation.

15. The method of claim 14 further comprising measuring arterial blood pressure and wherein the assessment of cardiac function further includes the measured arterial blood pressure.

16. The method of claim 14 further comprising measuring exertion level wherein the assessment of cardiac function further includes the measured exertion level.

17. The method of claim 14 further comprising measuring heart rate variability, assessing the patient'"'"'s autonomic balance based upon the measured heart rate variability, and wherein the assessment of cardiac function further includes the assessment of the patient'"'"'s autonomic balance based upon heart rate variability.

18. The method of claim 14 wherein the anti-remodeling therapy further includes inhibition of sympathetic nerve activity.